December 8, 2016
Novartis gets eye disease drug European approval
European Commission (EC) has granted an additional indication for Novartis’s Lucentis (ranibizumab) to treat patients with eye disease due to…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
December 8, 2016
Erytech places shares, funds acute leukemia drug
Acute leukemia focused pharmaceutical company Erytech Pharma, has announced the closing of a private placement of 793,877 ordinary shares to…
December 8, 2016
Novartis gets positive COPD related study results
Novartis on Wednesday announced positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating…
December 8, 2016
Bristol-Myers raises its quarterly dividend
Bristol-Myers Squibb Company has declared an increase of 2.6% percent in the its quarterly dividend, beginning in the first quarter…
December 8, 2016
ValiRx’s prostate cancer drug gets European patent
European Patent Office has granted ValiRx’s patent covering its major therapeutic compound VAL201, including prostate cancer, the pharmaceutical company said on…
December 8, 2016
Hair care company places shares, raises half million
InnovaDerma, a UK -based company focused on hair loss, hair care, self-tanning and skin rejuvenation, has raised £539,999.60 through the…
December 8, 2016
Bayer buys BIVI’s animal health products in US
Bayer and Boehringer Ingelheim Vetmedica, Inc. (BIVI) have made a deal for Bayer to buy BIVI’s Cydectin bovine and ovine…
December 7, 2016
Biocartis launches second liquid biopsy assay
Biocartis Group NV has launched its second liquid biopsy assay, the Idylla ctKRAS Mutation Assay, which was developed in partnership…
December 7, 2016
Neovac’s Lupus vaccine on USFDA’s fast track
The U.S. Food and Drug Administration (FDA) has granted “Fast Track” status to French biopharmaceutical company Neovacs’s IFNalpha Kinoid in…
December 7, 2016
GeNeuro, Servierhave extend multiple sclerosis study
GeNeuro and Servierhave set up a study they named ANGEL-MS, which is a long-term extension study for patients with multiple sclerosis…